Table 2 Participants who used and had their regimens changed and the duration of use
Antiretroviral therapy regimens | Participants who ever received regimen | Participants who had their regimen changed (%)a | Median ART duration in months (IQR) | Range of ART duration in months |
|---|---|---|---|---|
Zidovudine-lamivudine-nevirapine | 83 | 43 (52.4%) | 9 (7–14) | 1–47 |
Tenofovir-lamivudine-nevirapine | 65 | 20 (30.8%) | 2 (2–3) | 1–24 |
Stavudine-lamivudine-nevirapine | 53 | 53 (100%) | 58 (37–80) | 8–110 |
Zidovudine-lamivudine-efavirenz | 15 | 10 (66.7%) | 13 (2–24) | 1–69 |
Tenofovir-lamivudine-efavirenz | 9 | 2 (22.2%) | 9 (7–14) | 1–47 |
Tenofovir-emcitrabine-nevirapine | 2 | 0 (0.0%) | 3 (2–4) | 2–4 |
Tenofovir-emcitrabine-efavirenz | 1 | 1 (100%) | 29 (29–29) | 29 |